Slide 1: 2013 Financial Year Results
For personal use only 2013 Financial Year Results 29 August 2013
Slide 2: Cautionary Note Regarding Forward-Looking Statements
For personal use only CAUTIONARY NOTE REGARDING FORWARD‐LOOKING STATEMENTS This presentation, including any comments made during or following the presentation, may contain forward‐looking statements that are inherently subject to risks and uncertainties, some of which cannot be predicted or quantifi
Slide 3: Financial Results Snapshot
Financial Results Snapshot For personal use only Results 2013 2012 Total revenue & other income 34.7M 38.3M Operating expenses R&D 43.1M 36.9M Manufacturing 20.9M 22.0M Management 30.7M 28.1M Income tax expense 1.7M 22.4M (Losses) / profit after tax (61.7M) (71.1M) EPS basic – cents per share (21.06
Slide 4: Financial Results Snapshot
Financial Results Snapshot For personal use only 3
Slide 5: Shareholder value and ownership
Shareholder value and ownership For personal use only Market valuation Issued shares 316.5 million Current share price (market close, August 28 2013) $5.62 Market capitalization, circa $1.78 billion Cash reserves $315.3 million Shareholder ownership Institutions/sophisticated investors 18% 24% Retai
Slide 6: Strategic focus
Strategic focus For personal use only Mesoblast’s corporate strategy is to: leverage proprietary cell‐based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin our future financial growth t
Slide 7: Strong Cash Position Enables Execution Of Late-Stage Clinical Trials
Strong Cash Position Enables Execution Of Late‐Stage Clinical Trials For personal use only Completed $170 million financing from targeted global financial investors Total working capital of $315.3 million will be used to ‐ execute additional Phase 3 trials ‐ broaden our clinical development progra
Slide 8: Mechanisms of Action Drive Product Development
Mechanisms of Action (MOA) Drive Product Development For personal use only Mesoblast's strategic product focus is guided by specific MOAs of our MPCs. The MPCs respond to signals from inflammation and /or tissue damage by releasing a range of factors which : induce polarization of pro‐inflammatory
Slide 9: Cell-based Technologies Deliver Multiple Product Pipeline
Cell-based Technologies Deliver Multiple Product Pipeline PRODUCTS PRECLINICAL PHASE 2 PHASE 3 SUBMIT FOR FDA APPROVAL =» TTR RRER 2hewrratoia arthritis AATEC 4s:hm2/euimonary torosis AOAC CTA ERR RRREER *y0< 2 ciaberes OTTER 2%2b2tic complications (kidney) TCT R EERE RRR RRREE see tesion OCALA ECAR
Slide 10: Major accomplishments – immune/inflammatory disorders treated intravenously with MPCs
Major accomplishments – immune/inflammatory disorders treated intravenously with MPCs For personal use only Diabetes Completed enrollment of 60‐patient Phase 2 trial evaluating single intravenous MPC injection in patients with early type 2 diabetes not adequately controlled on oral glucose‐reducin
Slide 11: Major accomplishments – spinal diseases
Major accomplishments – spinal diseases For personal use only Spinal fusion product Phase 2 trial in lumbar fusion demonstrated equivalence of MPC treatment at 12 months with autogenous hip autograft in terms of radiographic fusion, pain reduction, and improvement in function Data are being used
Slide 12: Major accomplishments – strategic partnerships
Major accomplishments – strategic partnerships For personal use only Phase 2 trial for congestive heart failure closed as per protocol after all patients completed three years of follow‐up. The complete dataset showed that patients treated with the highest MPC dose have not experienced any hospita
Slide 13: Major accomplishments − intellectual property
Major accomplishments − intellectual property For personal use only Significantly expanded patent portfolio to support long‐term business goals of protecting our products as we broaden our access to and penetration of global markets Key patents granted by the US Patent and Trademark Office and t
Slide 14: The year ahead, what we expect
The year ahead, what we expect For personal use only Commencement of Phase 3 trial for congestive heart failure involving an early interim analysis to evaluate evidence of efficacy Commencement of a Phase 3 trial for spinal fusion Results of full dataset for Phase 2 trial in intervertebral dis
Slide 15: Leading the world in adult stem cell therapies
For personal use only Leading the world in adult stem cell therapies